|
| No prophylactic therapy | Prophylactic therapy (lamivudine) | Prophylactic therapy (entecavir) | P-value |
| Histology |
|
|
|
|
| B-NHL | 42 | 52 | 52 |
|
| ECOG |
|
|
|
|
| 0 or 1 | 41 | 50 | 48 | 0.15 |
| >1 | 1 | 2 | 4 |
|
| Chemotherapy regimen |
|
|
|
|
| CHOP | 42 | 49 | 52 | 0.33 |
| Hyper CVAD | 0 | 3 | 2 |
|
| Normal baseline ALT | 38 | 52 | 52 | 0.61 |
| No. of patients HBV DNA monitored | 42 | 52 | 52 |
|
| Incidence of hepatitis (Total) | 22 (52.4%) | 12 (23.1%) | 2 (3.85%) | P = 0.000a1 P = 0.006a2 P = 0.000a3 P = 0.01a4 |
| HBV-reactivation | 21(50.0%) | 10(19.2%) | 1(1.92%) | P = 0.000a1 P = 0.001a2 P = 0.000a3 P = 0.013a4 |
| Interrupt of planned chemotherapy | 7(16.7%) | 2(3.85%) | 0(0%) |
|